APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medication

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Medication Market Outlook and Growth Opportunities 2026

22 December 2025205 pages

Choose your research edition.

Industry ResearchMedication Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Medication Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medication Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Medication Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Medication market include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Medication market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medication and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medication revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Medication market.

Medication Segment by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Roche

Eli Lilly

Pfizer

GlaxoSmithKline (GSK)

Bayer

Amgen

AbbVie

AbbVie

AstraZeneca

Merck & Co. (MSD)

Gilead Sciences

Bristol-Myers Squibb

Boehringer Ingelheim

Medication Segment by Type

Brand Drugs

Generic Drug

Medication Segment by Application

Hospital

Clinic

Other

Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Medication status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Medication key companies, revenue, market share, and recent developments.

3. To split the Medication breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Medication market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Medication significant trends, drivers, influence factors in global and regions.

6. To analyze Medication competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medication industry.

Chapter 3: Detailed analysis of Medication company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Medication in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Medication Industry Trends Table 2. Medication Industry Drivers Table 3. Medication Industry Opportunities and Challenges Table 4. Medication Industry Restraints Table 5. Global Medication Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Medication Revenue Share by Company (2021-2026) Table 7. Global Medication Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Medication Key Company Manufacturing Base & Headquarters Table 9. Global Medication Company, Product Type & Application Table 10. Global Medication Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Brand Drugs Table 15. Significant Companies of Generic Drug Table 16. Global Medication Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Medication Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Medication Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Medication Sales Value Share by Type (2021-2026) Table 20. Global Medication Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Medication Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Medication Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Medication Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Medication Sales Value Share by Application (2021-2026) Table 28. Global Medication Sales Value Share by Application (2027-2032) Table 29. Global Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Medication Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Medication Sales Value Share by Region (2021-2026) Table 32. Global Medication Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Medication Sales Value Share by Region (2027-2032) Table 34. Global Medication Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Medication Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Medication Sales Value Market Share by Country (2021-2026) Table 37. Global Medication Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Medication Sales Value Market Share by Country (2027-2032) Table 39. Takeda Company Information Table 40. Takeda Business Overview Table 41. Takeda Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Takeda Medication Product Portfolio Table 43. Takeda Recent Development Table 44. Teva Company Information Table 45. Teva Business Overview Table 46. Teva Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Teva Medication Product Portfolio Table 48. Teva Recent Development Table 49. Sanofi Company Information Table 50. Sanofi Business Overview Table 51. Sanofi Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi Medication Product Portfolio Table 53. Sanofi Recent Development Table 54. Johnson & Johnson Company Information Table 55. Johnson & Johnson Business Overview Table 56. Johnson & Johnson Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Johnson & Johnson Medication Product Portfolio Table 58. Johnson & Johnson Recent Development Table 59. Novartis Company Information Table 60. Novartis Business Overview Table 61. Novartis Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Novartis Medication Product Portfolio Table 63. Novartis Recent Development Table 64. Novo Nordisk Company Information Table 65. Novo Nordisk Business Overview Table 66. Novo Nordisk Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novo Nordisk Medication Product Portfolio Table 68. Novo Nordisk Recent Development Table 69. Roche Company Information Table 70. Roche Business Overview Table 71. Roche Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Roche Medication Product Portfolio Table 73. Roche Recent Development Table 74. Eli Lilly Company Information Table 75. Eli Lilly Business Overview Table 76. Eli Lilly Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eli Lilly Medication Product Portfolio Table 78. Eli Lilly Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Medication Product Portfolio Table 83. Pfizer Recent Development Table 84. GlaxoSmithKline (GSK) Company Information Table 85. GlaxoSmithKline (GSK) Business Overview Table 86. GlaxoSmithKline (GSK) Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline (GSK) Medication Product Portfolio Table 88. GlaxoSmithKline (GSK) Recent Development Table 89. Bayer Company Information Table 90. Bayer Business Overview Table 91. Bayer Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Bayer Medication Product Portfolio Table 93. Bayer Recent Development Table 94. Amgen Company Information Table 95. Amgen Business Overview Table 96. Amgen Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Amgen Medication Product Portfolio Table 98. Amgen Recent Development Table 99. AbbVie Company Information Table 100. AbbVie Business Overview Table 101. AbbVie Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. AbbVie Medication Product Portfolio Table 103. AbbVie Recent Development Table 104. AbbVie Company Information Table 105. AbbVie Business Overview Table 106. AbbVie Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. AbbVie Medication Product Portfolio Table 108. AbbVie Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. AstraZeneca Medication Product Portfolio Table 113. AstraZeneca Recent Development Table 114. Merck & Co. (MSD) Company Information Table 115. Merck & Co. (MSD) Business Overview Table 116. Merck & Co. (MSD) Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Merck & Co. (MSD) Medication Product Portfolio Table 118. Merck & Co. (MSD) Recent Development Table 119. Gilead Sciences Company Information Table 120. Gilead Sciences Business Overview Table 121. Gilead Sciences Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Gilead Sciences Medication Product Portfolio Table 123. Gilead Sciences Recent Development Table 124. Bristol-Myers Squibb Company Information Table 125. Bristol-Myers Squibb Business Overview Table 126. Bristol-Myers Squibb Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Bristol-Myers Squibb Medication Product Portfolio Table 128. Bristol-Myers Squibb Recent Development Table 129. Boehringer Ingelheim Company Information Table 130. Boehringer Ingelheim Business Overview Table 131. Boehringer Ingelheim Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Boehringer Ingelheim Medication Product Portfolio Table 133. Boehringer Ingelheim Recent Development Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Medication Product Image Figure 2. Global Medication Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medication Market Size (2021-2032) & (US$ Million) Figure 4. Global Medication Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Brand Drugs Image Figure 8. Generic Drug Image Figure 9. Global Medication Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Medication Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Medication Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Medication Sales Value Share by Application (2021-2032) Figure 18. Global Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Medication Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Medication Sales Value (2021-2032) & (US$ Million) Figure 21. North America Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Medication Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Medication Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Medication Sales Value (2021-2032) & (US$ Million) Figure 27. South America Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Medication Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Brand Drugs
  • Generic Drug
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline (GSK)
  • Bayer
  • Amgen
  • AbbVie
  • AbbVie
  • AstraZeneca
  • Merck & Co. (MSD)
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Medication Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Medication Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Medication Market Dynamics
  1. 2.1 Medication Industry Trends
  2. 2.2 Medication Industry Drivers
  3. 2.3 Medication Industry Opportunities and Challenges
  4. 2.4 Medication Industry Restraints
3 Medication Market by Company
  1. 3.1 Global Medication Company Revenue Ranking in 2025
  2. 3.2 Global Medication Revenue by Company (2021-2026)
  3. 3.3 Global Medication Company Ranking (2024-2026)
  4. 3.4 Global Medication Company Manufacturing Base and Headquarters
  5. 3.5 Global Medication Company Product Type and Application
  6. 3.6 Global Medication Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Medication Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Medication Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Medication Market by Type
  1. 4.1 Medication Type Introduction
  2. 4.1.1 Brand Drugs
  3. 4.1.2 Generic Drug
  4. 4.2 Global Medication Sales Value by Type
  5. 4.2.1 Global Medication Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Medication Sales Value by Type (2021-2032)
  7. 4.2.3 Global Medication Sales Value Share by Type (2021-2032)
5 Medication Market by Application
  1. 5.1 Medication Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Medication Sales Value by Application
  6. 5.2.1 Global Medication Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Medication Sales Value by Application (2021-2032)
  8. 5.2.3 Global Medication Sales Value Share by Application (2021-2032)
6 Medication Regional Value Analysis
  1. 6.1 Global Medication Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medication Sales Value by Region (2021-2032)
  3. 6.2.1 Global Medication Sales Value by Region: 2021-2026
  4. 6.2.2 Global Medication Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Medication Sales Value (2021-2032)
  7. 6.3.2 North America Medication Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Medication Sales Value (2021-2032)
  10. 6.4.2 Europe Medication Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Medication Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Medication Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Medication Sales Value (2021-2032)
  16. 6.6.2 South America Medication Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Medication Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Medication Sales Value Share by Country, 2025 VS 2032
7 Medication Country-level Value Analysis
  1. 7.1 Global Medication Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Medication Sales Value by Country (2021-2032)
  3. 7.2.1 Global Medication Sales Value by Country (2021-2026)
  4. 7.2.2 Global Medication Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Medication Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Medication Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Medication Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Medication Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Medication Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Medication Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Medication Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Medication Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Medication Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Medication Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Medication Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Medication Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Medication Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Medication Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Medication Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Medication Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Medication Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Medication Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Medication Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Medication Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Medication Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Medication Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Medication Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Medication Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Medication Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Medication Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Medication Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Medication Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Medication Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Medication Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Medication Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Medication Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Medication Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Medication Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Medication Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Medication Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Medication Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Medication Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Medication Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Medication Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Medication Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Medication Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Medication Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Medication Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Medication Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Medication Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Medication Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Medication Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Medication Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Medication Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Medication Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Medication Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Medication Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Medication Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Medication Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Medication Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Medication Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Medication Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Medication Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Medication Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Medication Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Medication Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Medication Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Medication Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Medication Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Medication Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Medication Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Medication Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Medication Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Medication Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Medication Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Medication Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Medication Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Medication Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Medication Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Medication Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Medication Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Medication Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Medication Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Medication Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Medication Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Medication Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Medication Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Medication Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Medication Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Medication Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Medication Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Medication Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Medication Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Medication Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Medication Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Medication Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Medication Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Medication Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Medication Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Medication Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Medication Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Medication Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Medication Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Medication Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Medication Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Medication Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 GlaxoSmithKline (GSK)
  56. 8.10.1 GlaxoSmithKline (GSK) Company Information
  57. 8.10.2 GlaxoSmithKline (GSK) Business Overview
  58. 8.10.3 GlaxoSmithKline (GSK) Medication Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline (GSK) Medication Product Portfolio
  60. 8.10.5 GlaxoSmithKline (GSK) Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Medication Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Medication Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Medication Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Medication Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Medication Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Medication Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 AbbVie
  80. 8.14.1 AbbVie Company Information
  81. 8.14.2 AbbVie Business Overview
  82. 8.14.3 AbbVie Medication Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AbbVie Medication Product Portfolio
  84. 8.14.5 AbbVie Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca Medication Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca Medication Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 Merck & Co. (MSD)
  92. 8.16.1 Merck & Co. (MSD) Company Information
  93. 8.16.2 Merck & Co. (MSD) Business Overview
  94. 8.16.3 Merck & Co. (MSD) Medication Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck & Co. (MSD) Medication Product Portfolio
  96. 8.16.5 Merck & Co. (MSD) Recent Developments
  97. 8.17 Gilead Sciences
  98. 8.17.1 Gilead Sciences Company Information
  99. 8.17.2 Gilead Sciences Business Overview
  100. 8.17.3 Gilead Sciences Medication Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Gilead Sciences Medication Product Portfolio
  102. 8.17.5 Gilead Sciences Recent Developments
  103. 8.18 Bristol-Myers Squibb
  104. 8.18.1 Bristol-Myers Squibb Company Information
  105. 8.18.2 Bristol-Myers Squibb Business Overview
  106. 8.18.3 Bristol-Myers Squibb Medication Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bristol-Myers Squibb Medication Product Portfolio
  108. 8.18.5 Bristol-Myers Squibb Recent Developments
  109. 8.19 Boehringer Ingelheim
  110. 8.19.1 Boehringer Ingelheim Company Information
  111. 8.19.2 Boehringer Ingelheim Business Overview
  112. 8.19.3 Boehringer Ingelheim Medication Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Boehringer Ingelheim Medication Product Portfolio
  114. 8.19.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst